Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage, ophthalmology-focused biopharmaceutical company developing novel therapies for neuropathic corneal pain (NCP), dry eye disease, and other ocular inflammatory conditions. Its news flow centers on the progress of its lead investigational drug candidate, urcosimod, and related clinical, regulatory, and corporate developments.
Visitors to this news page can review company-issued announcements about Phase 2 clinical trial results, including data showing reductions in neuropathic corneal pain and exploratory findings on corneal nerve structure in NCP patients treated with urcosimod. OKYO also reports on earlier Phase 2 results in dry eye disease, where urcosimod demonstrated statistically significant outcomes on multiple endpoints in a 240-patient trial.
In addition to clinical data, OKYO’s news releases cover planned development milestones such as the registration pathway and a proposed multiple-ascending-dose, multi-center trial in approximately 100 NCP patients, as well as references to urcosimod’s Fast-Track designation and anticipated regulatory interactions. Corporate communications include participation in ophthalmology and life science conferences, such as the Ophthalmology Innovation Summit and BIO-Europe, where management presents updates on urcosimod and the company’s pipeline.
Investors can also find announcements related to share acquisitions by Panetta Partners Limited, an entity with a beneficial interest held by OKYO’s Executive Chairman, as disclosed in both news releases and accompanying Form 6-K filings. Together, these updates provide a view into how OKYO is advancing urcosimod as a potential first-in-class therapy for neuropathic corneal pain and dry eye disease, and how it communicates key milestones to the market.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced its participation in the Biotech Showcase in San Francisco from January 9-11, 2023. The company focuses on developing OK-101 to treat dry eye disease, addressing significant unmet needs in this multi-billion-dollar market. CEO Dr. Gary Jacob and other executives will present and hold 1x1 institutional investor meetings during the event. Attendees can schedule meetings online. The event highlights OKYO's commitment to innovation in treating inflammatory dry eye diseases.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has filed a Form F-1 registration statement with the SEC for a secondary public offering of its American Depositary Shares (ADSs). Each ADS will represent 65 ordinary shares. The offering's size and price are yet to be determined and depend on market conditions. This offering, approved by shareholders at the September 2022 AGM, will allow OKYO's shares to continue trading on the LSE and NASDAQ. ThinkEquity is the sole bookrunning manager, and the offering will not be available in the EEA or UK to the public.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) appointed PKF Littlejohn LLP as its new independent auditor effective immediately. The board approved PKF for the financial year ending March 31, 2023, with re-appointment subject to shareholder approval at the next AGM in 2023. The previous auditor, Mazars LLP, confirmed no matters for the Company’s members or creditors. OKYO thanks Mazars for their service. This announcement contains inside information under UK market regulations.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has awarded Chief Scientific Officer Raj Patil 5,000,000 options with an exercise price of 6.25 pence per share, recognizing his contribution to the recent IND filing for OK-101, aimed at treating dry eye disease. The options vest immediately and have a five-year lifespan. This move highlights the company's advancement in developing therapies for the significant unmet needs in the dry eye market, which is valued in the billions. The announcement complies with UK MAR regulations.
OKYO Pharma Ltd (NASDAQ: OKYO) announced a Key Opinion Leader webinar on November 14, 2022, regarding its potential treatment, OK-101, for inflammatory dry eye disease. The event features KOL Pedram Hamrah, MD, discussing preclinical data on OK-101's efficacy. The company aims to address a significant market need in dry eye therapies and will provide updates on its Phase 2 trial for OK-101, a lipid-conjugated peptide targeting ocular pain and inflammation.
OKYO Pharma Limited (NASDAQ: OKYO) announced its CEO, Dr. Gary Jacob, will be featured on The RedChip Money Report on Bloomberg TV on September 10, 2022. The interview will cover the company's NASDAQ listing, plans for a Phase 2 study for Dry Eye Disease, and expectations for top-line data. This access expands OKYO's visibility as it operates in the biotechnology sector, focusing on new treatments for inflammatory dry eye diseases and ocular pain.
OKYO Pharma Limited (NASDAQ: OKYO) announced an upcoming interview with CEO Dr. Gary Jacob on the RedChip Money Report airing on Bloomberg TV on September 10, 2022, at 7 p.m. ET. The interview will cover the company's NASDAQ listing and plans for a Phase 2 study for Dry Eye Disease, including anticipated top-line data. OKYO focuses on developing novel treatments for inflammatory dry eye diseases and chronic pain, and is listed on both NASDAQ and the London Stock Exchange.
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed. The voting results showed overwhelming support, with key resolutions such as the approval of the report and accounts receiving 99.99852% approval. Shareholders, totaling 1,415,040,468 ordinary shares, participated actively in the voting process. The resolutions included the re-election of directors and the appointment of auditors, reflecting strong governance practices and shareholder confidence in the company's direction.
OKYO Pharma Limited is gearing up for a Q4 2022 IND filing for OK-101, targeting dry eye disease (DED) and supported by AmbioPharm. Following a successful pre-IND meeting with the FDA in Q1 2022, the Phase 2 trial is set to commence in Q1 2023, designed to expedite market entry. OK-101, a lipid-peptide analog, showcases potent anti-inflammatory properties in animal models, addressing a significant unmet need in the multibillion-dollar DED market.
OKYO Pharma Limited (NASDAQ: OKYO) announced its audited results for the year ending March 31, 2022. They reported a comprehensive loss of £3,976k and a cash balance of £2,056k. The company is advancing its lead candidate OK-101 for dry eye disease (DED) and plans to file an IND by Q4 2022, followed by a Phase 2 trial in early 2023. Preclinical studies showed significant efficacy for OK-101 in reducing corneal permeability and pain, with potential future evaluations for uveitis and allergic conjunctivitis.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
